Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.
about
Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicityPotent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating eventAnti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cellsHP 0.35, a cephalosporin degradation product is a specific inhibitor of lentiviral RNAses HNonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replicationSynergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitroIn vivo evaluation of the anemia induced by azidothymidine (AZT) in a murine model of AIDSMechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variantsSynergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytesLong-term AZT exposure alters the metabolic capacity of cultured human lymphoblastoid cellsPharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance studyZalcitabine population pharmacokinetics: application of radioimmunoassay.A mechanistic view of human mitochondrial DNA polymerase gamma: providing insight into drug toxicity and mitochondrial diseaseComparison of rates of intracellular metabolism of zidovudine in human and primate peripheral blood mononuclear cells.Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patientsA novel LC-MS/MS method for simultaneous quantification of tenofovir and lamivudine in human plasma and its application to a pharmacokinetic study.Science, medicine and clinical pharmacology. The Lilly Lecture 1994.Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide.Zidovudine (Retrovir) updatePreventing secondary infections among HIV-positive persons.Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virusMechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcriptionClarithromycin does not affect phosphorylation of zidovudine in vitroCorrelations between the in vitro and in vivo activity of anti-HIV agents: implications for future drug development.Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.Didanosine.Antiretroviral therapy: reverse transcriptase inhibition.In vitro activities of nucleoside analog antiviral agents against salmonellaeEffect of zidovudine on preimplantation murine embryosOnce-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition.Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS.Antiviral therapy: current concepts and practicesPharmacokinetic interaction between zidovudine and trimethoprim/sulphamethoxazole in HIV-1 infected childrenHuman immunodeficiency virus infection in Northern Ireland 1980-1989Central nervous system targeting of 2',3'-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugsPre- and postexposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine responseEarly upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.Impairment of tritan colour vision after initiation of treatment with zidovudine in patients with HIV disease or AIDS.
P2860
Q24649755-81C7233D-C40E-4231-8BA2-AD430602A8B0Q28320362-DF4E69F6-4494-4C1A-B69F-4BAE4DDBD33AQ28323830-EF0253A4-6E93-403E-BE7A-9C28D38A0AEBQ28324003-6057216E-4270-44EF-99B5-05E620CA319BQ28324100-59F59E9B-1E59-4AF8-BEBA-3227E6660349Q28326720-B4C3372C-4819-437E-A9AF-DCD8E8656B89Q28333060-4BE00303-5482-4E1F-A83A-5C3281101155Q28343606-184ED838-A5E8-4AD6-B3A1-AACD927AD31FQ28369082-78650113-A198-4A68-8114-11476B04DDB9Q28394866-4419085F-6847-4371-963E-CAE1B94FA347Q28610375-AE15D55E-46C0-48B2-86F7-E1A8ACE38AC1Q33690050-7380DB90-F4F1-43F2-8E81-3F1DB4D617F2Q33756066-090DD17F-7AEB-4057-9B2F-F3D2973FA020Q33761409-73819C78-6D21-4E53-B537-BC6304164184Q33896043-936E269A-6FF0-4726-8623-9862AB00E7E2Q33900606-B2612DCD-C07D-4BA9-9E09-51060FC6B195Q33932937-803552A0-EE63-4326-AA7C-AD75F24E5785Q34119862-084ECB6A-7B00-4602-952F-271C6AB43145Q34347099-D94BBD7D-EC4F-4D4F-A27C-06D0F6FC881BQ34403379-6B84D9DA-6595-472D-9EE1-9960EEA75FE3Q34579638-797D2711-89E3-45C6-98B3-A26160C65563Q35055557-F2963974-161B-421D-8CA9-6893058ED619Q35122047-CA312092-8796-4FAD-905D-046698DE498AQ35122784-08F8CAEB-A53F-4483-8CDC-93DF8EB6A663Q35126325-876CFB09-BD04-470A-9241-ACCAD59391F1Q35174403-EEDECCF3-23AC-4ADE-9E7D-9454966646B8Q35178308-445E28CD-E7A1-44C1-BF0D-B5C574D9428CQ35255870-043C6849-95D8-45FA-AA77-50A858C5135FQ35322871-87716356-6D06-4314-B2AA-2E2433F2F65DQ35807765-759ACDB4-0B9A-4C89-A2D3-9AADDCC12AF6Q35817719-47579A63-22A4-45BA-A9A8-8E47FCD87277Q35836068-97A94716-75B5-4764-9413-F983FE69DA9FQ35897391-EA41B704-D134-479C-9988-78F5A128B06DQ36070394-12428328-3F34-4A0C-9884-7184BAD38FB2Q36170213-5F5426A2-6BBE-4BDA-9C23-901E5F67C1DCQ36750969-026EAF18-DC57-499A-83EE-E31D154BE233Q36757759-CC840FD9-83F6-4D42-A0FC-16863FF67491Q36758266-F45552B4-CCDD-4181-9FD3-F32EDBCE2D23Q36813326-B02EE68B-17C8-4938-A0ED-DF9A5D59B3ECQ37301213-10396BDA-52D2-401F-A1CC-90340220F0B0
P2860
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.
description
1989 nî lūn-bûn
@nan
1989 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
name
Clinical pharmacology of 3'-az ...... nd related dideoxynucleosides.
@ast
Clinical pharmacology of 3'-az ...... nd related dideoxynucleosides.
@en
Clinical pharmacology of 3'-az ...... nd related dideoxynucleosides.
@nl
type
label
Clinical pharmacology of 3'-az ...... nd related dideoxynucleosides.
@ast
Clinical pharmacology of 3'-az ...... nd related dideoxynucleosides.
@en
Clinical pharmacology of 3'-az ...... nd related dideoxynucleosides.
@nl
prefLabel
Clinical pharmacology of 3'-az ...... nd related dideoxynucleosides.
@ast
Clinical pharmacology of 3'-az ...... nd related dideoxynucleosides.
@en
Clinical pharmacology of 3'-az ...... nd related dideoxynucleosides.
@nl
P2093
P1476
Clinical pharmacology of 3'-az ...... nd related dideoxynucleosides.
@en
P2093
P304
P356
10.1056/NEJM198909143211106
P407
P577
1989-09-01T00:00:00Z